Thus, MET exerts an antitumor action against cervical carcinoma, colorectal tumor, cutaneous squamous cell carcinoma, and breast, gastric, lung, ovarian, renal, and thyroid cancers. This evidence concerns the gene MET and cervical carcinoma.